Evidence map›Paper›PMID 36585575›Full record

ArticleJournal of cancer survivorship : research and practice2023

Quality of life of patients with rare cancer: a comparison with patients with colorectal cancer and the association with disease trajectory-related factors.

Esmee Driehuis, Eline de Heus, Marga Schrieks, Vivian Engelen, Tineke E Buffart, Geraldine R Vink, Saskia F A Duijts

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in Journal of cancer survivorship : research and practice, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Diagnostic trajectories of patients with rare cancer in the Netherlands: results from a nationwide cross-sectional survey.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 2 countries.

Esmee DriehuisDepartment of Research and Development, Netherlands Comprehensive Cancer Organisation (Integraal Kankercentrum Nederland, IKNL), Godebaldkwartier 419, 3511 DT, Utrecht, The Netherlands.
Eline de HeusDepartment of Research and Development, Netherlands Comprehensive Cancer Organisation (Integraal Kankercentrum Nederland, IKNL), Godebaldkwartier 419, 3511 DT, Utrecht, The Netherlands.
Marga SchrieksDutch Federation of Cancer Patients Organizations, Nederlandse Federatie Van Kankerpatiëntenorganisaties, NFK), Godebaldkwartier 365, 3611 DT, Utrecht, The Netherlands.
Vivian EngelenDutch Federation of Cancer Patients Organizations, Nederlandse Federatie Van Kankerpatiëntenorganisaties, NFK), Godebaldkwartier 365, 3611 DT, Utrecht, The Netherlands.
Tineke E BuffartDepartment of Medical Oncology, Amsterdam University Medical Centers (Location VUmc), De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.
Geraldine R VinkDepartment of Research and Development, Netherlands Comprehensive Cancer Organisation (Integraal Kankercentrum Nederland, IKNL), Godebaldkwartier 419, 3511 DT, Utrecht, The Netherlands.
Saskia F A DuijtsDepartment of Research and Development, Netherlands Comprehensive Cancer Organisation (Integraal Kankercentrum Nederland, IKNL), Godebaldkwartier 419, 3511 DT, Utrecht, The Netherlands. s.duijts@iknl.nl.
Amsterdam University Medical Centers · NLNetherlands Federation of University Medical Centres · NLHeidelberg University · DENetherlands Comprehensive Cancer Organisation · NLRadboud University Medical Center · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeDifferences in quality of life (QoL) between patients with rare and common cancer might be explained by the specific challenges patients with rare cancer face during their disease trajectory, but research is scarce. This study aimed to (1) assess the difference in QoL between patients with rare and common cancer (i.e. colorectal cancer (CRC)) and (2) examine the association between disease trajectory-related factors and QoL in patients with rare cancer.

methodsCross-sectional data were collected among adults with rare cancer by a nationwide online survey in the Netherlands. For comparison with patients with CRC, data from the Prospective Dutch Colorectal Cancer (PLCRC) cohort were used. Associations were assessed by linear regression analyses.

resultsData from 1525 patients with rare cancer and 1047 patients with CRC were analysed. Having a rare cancer was significantly associated with a lower QoL compared to having CRC (p < 0.001). Disease trajectory-related factors significantly associated with QoL in patients with rare cancer were time until diagnosis, misdiagnoses, information on best treatment options, information on late and/or long-term effects, and both satisfaction with physician and specialized nurse care (all: p < 0.05).

conclusionPatients with rare cancers have a lower self-reported QoL than patients with CRC, and several disease trajectory-related factors are associated with QoL in patients with rare cancer. IMPLICATIONS FOR CANCER SURVIVORS: To improve QoL of patients with rare cancer, appropriate guidance and support by healthcare professionals throughout the disease trajectory are needed, as well as early diagnosis and proper referral to centres of expertise.

Indexed as

Cancer SurvivorsColorectal NeoplasmsAdultCross-Sectional StudiesHumansProspective StudiesQuality of LifeSurveys and QuestionnairesCancer careColorectal cancerQuality of life (QoL)Rare cancer

Identifiers

PMID36585575
OpenAlexW4313340139

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.